The hybridization of heterocycles presents a key opportunity to craft innovative multicyclic
compounds with enhanced biological activity. Coumarins, being broadly prevalent natural …

Although idiopathic pulmonary fibrosis (IPF) is the most well studied among the fibrotic
interstitial lung diseases (ILDs), non-IPF fibrotic lung diseases may also have a progressive …

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and fatal interstitial pneumonia
with unknown pathogenesis. Early diagnosis and therapeutic intervention are essential for …

Idiopathic pulmonary fibrosis (IPF) is a chronic inflammatory disease destroying lungs
irreversibly with high mortality rates. There are challenges in diagnosing IPF and treating it …

Idiopathic pulmonary fibrosis (IPF), whose early diagnosis and effective treatment still
remain the focus of clinical studies, is a chronic, irreversible and finally fatal pulmonary …

Idiopathic pulmonary fibrosis is a progressive and incurable lung disease characterized by
collagen deposition, alveolar inflammation, fibroblast proliferation, and the destruction of …

End-of-life care (EOLC) is palliative support provided in the last 6 months to 1 year of a
patient's life. Although there are established criteria for its indication, few studies describe …

Abstract Background and Objective Interstitial lung disease (ILD) is progressive with high
symptom burdens and poor prognosis. Patients with ILD need optimal palliative care to …

Purpose This article summarizes the appropriate use and pharmacology of treatments for
fibrosing interstitial lung diseases, with a specific focus on the antifibrotic agents nintedanib …

Background Acute exacerbation (AE) is a major cause of death in patients with idiopathic
pulmonary fibrosis (IPF). AE-IPF patients require optimal palliative care; however, the real …